Beyond cardiovascular medicine: potential future uses of icosapent ethyl - Sorbonne Université
Journal Articles European Heart Journal Supplements Year : 2020

Beyond cardiovascular medicine: potential future uses of icosapent ethyl

Abstract

The REDUCE-IT trial demonstrated that icosapent ethyl, an ethyl ester of eicosapentaenoic acid (EPA), reduced cardiovascular events in an at-risk population by a substantial degree. While the cardiovascular protective properties of this compound are now proven, several other potential uses are being actively explored in clinical studies. These areas of investigation include cancer, inflammatory bowel disease, infections, Alzheimer's disease, dementia, and depression. The next decade promises to deepen our understanding of the beneficial effects that EPA may offer beyond cardiovascular risk reduction.
Fichier principal
Vignette du fichier
suaa119.pdf (457.16 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03145015 , version 1 (18-02-2021)

Identifiers

Cite

Carol van Hulle, Deepak Bhatt, Mark A Hull, Mingyang Song, Cindy Carlsson, et al.. Beyond cardiovascular medicine: potential future uses of icosapent ethyl. European Heart Journal Supplements, 2020, 22 (Supplement_J), pp.J54-J64. ⟨10.1093/eurheartj/suaa119⟩. ⟨hal-03145015⟩
16 View
54 Download

Altmetric

Share

More